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Renin was discovered by the Finnish physiologist, 
Robert Tigerstedt, working with his medical 
student, Bergman, in Stockholm in 1898. They 
showed that saline extracts of fresh rabbit kidney 
or of an alcohol-dried powder produced an initial 
fall but then a prolonged rise in blood pressure 
when injected into rabbits lightly anesthetized 
with urethane [1, 2]. They also showed that renin 
could only be extracted from the renal cortex, that 
it was destroyed at 56°C, precipitated by half-
saturated ammonium sulfate, did not dialyze, had 
little effect on the heart, but also raised blood 
pressure of the pithed cat. For about three 
decades, very little else happened. When Myron 
Prinzmetal went to work with George Pickering, 
the two could initially not duplicate these 
findings. It was only when they used saline 
extracts of alcohol-dried kidney in unanesthetized 
rabbits that they achieved success. Franz Volhard 
and his assistants also stumbled on the problem 
of documenting the existence of renin. However, 
Volhard’s student, Hessel, eventually reported 
success in 1938. Greatly facilitating the notion that 
renin must exist were the renal artery stenosis 
studies of Harry Goldblat and collaborators in 
1934. In 1938, Fasciolo, Houssay, and Taquini 
showed that renal venous blood from an ischemic 
kidney produced vasoconstriction. Shortly 
thereafter, Braun-Menendez, Fasciolo, Leloir, and 
Munoz showed that the pressor substance was 
soluble in acetone, thermostable, and dialyzable, 
in short nothing at all like renin. They named the 
substance hypertensin. Independently, and in the 
same year, Irvine Page and Oscar Helmer, working 
in Indianapolis, IN, USA, found that renin was 
inactive when perfused in saline through the 
rabbit’s ear but that activity was restored by 
blood. They also showed that incubating renin 
with plasma produced a new substance that they 
called angiotonin. Both groups demonstrated that 
renin acts like an enzyme and a plasma protein as 
a substrate. In 1954, Skeggs, Marsh, Kahn, and 
Shumway, working at the Veterans Hospital in 
Cleveland, OH, USA, isolated two products from 
incubating hog renin with horse serum, 
hypertensin I and II. The group then showed that 
hypertensin II consists of the following eight 
amino-acids: Aspartic-Arginine-Valine-Tyrosine-
Isoleucine-Histidine-Proline-Phenylalanine. 
Hypertensin I is a decapeptide, with two 
additional amino acids, histidine and leucine, 
added to the phenylalanine end of the chain. 
Peart, while working in Pickering’s laboratory, 
largely confirmed these findings. The North and 
South Americans agreed to consolidate the 
nomenclature so that the deca- and octapeptides 
are termed angiotensin (Ang) I and Ang II, 
respectively. Thus, by 1956, the renin–angiotensin 
system was pretty well worked out. As a 
nephrologist, I would like to make a few more 
comments about Leonard Skeggs, who in my view 
is a largely unsung hero. Aside from the structure 
of Ang I and Ang II, Skeggs developed the plate 
hemodialyser that bears his name in 1948. This 
same technology was then adapted by Skeggs to 
develop the first automated device to perform 
blood chemistries. It was called the SMA-12-60 
autoanalyzer. Incidentally, the late Norman 
Shumway, who also appears on these papers, is 
much better known for his seminal contributions 
to cardiac transplantation. 
In 1958, Franz Gross published a brief history of 
renin, largely as I have recapitulated here [3]. In 
that paper, Gross made the startling suggestion 
that somehow renin stimulated aldostserone. He 
based this conclusion on data from his own 
laboratory. His group had found that treating 
animals with aldosterone and salt led to 
hypertension and a decrease in renal renin 
content. Adrenalectomy led to an increase in renal 
renin content. Aldosterone deficiency led to 
sodium loss, which in turn led to increased renin 
production. In bold strokes, Gross painted the 
picture of the major mechanisms controlling renin 
and aldosterone secretion. When Schwyzer 
succeeded in synthesizing Ang II in sufficient 
quantities for experimentation, Gross provided 
others with the material, just in case they might 
want to see what effect it had on aldosterone 
secretion. The schema proposed by Franz Gross is 
shown in Fig.1 and largely represents the renin–
angiotensin– aldosterone system as explained to 
me by Oscar Helmer in Indianapolis, IN, USA, 1968. 
Is renin solely a renal phenomenon? No, Ganten et 
al. showed that renin is also produced in the gut 
and in the brain [4,5]. Reports of renin-like activity 
in the female reproductive tract and in anephric 
dialysis patients were published at about the same 
time [6,7]. Numerous investigators worked on the 
existence of a relatively inactive material with a 
higher molecular weight than renin, termed “big 
renin.” Inagami and Murakami were able to isolate 
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relatively inactive big forms could be activated by 
acid, cold storage, and catalytic reactions. Sealey 
and Laragh examined this question extensively 
and further developed the notion of “pro”renin 
[9]. Luetscher and colleagues assayed renin and 
prorenin in patients with diabetes and made the 
seminal, largely ignored at the time, observation 
that prorenin correlated much better with 
diabetic complications than did renin levels [10]. 
Patients with high prorenin concentrations 
developed renal failure, blindness, and 
neuropathy. Diabetics generally have low plasma 
renin activity but relatively high prorenin levels. 
The notion of inhibiting renin to lower blood 
pressure and its sequellae was not lost on 
pharmacologists, and early attempts were made 
at developing nonimmunological renin inhibitors 
[11]. The history of this chapter is interesting, 
fraught with failure, and only recently crowned 
with success. A temporally better approach 
turned out to be inhibition of the angiotensin-
converting enzyme (ACE). Skeggs and colleagues 
had shown by their work that conversion of Ang I 
to Ang II was necessary to increase blood 
pressure. ACE was found to be largely tissue-
bound and particularly abundant in the 
pulmonary vascular bed. The enzyme is a Zn-
containing matrix metalloproteinase. Ferreira 
made the keynote observation that Bothrops 
jararaca venom contained a material that 
potentiated bradykinin [12]. Ondetti et al [13] 
determined the structure of the bradykinin-
potentiating factors and also observed that the 
peptides diminished the increase in blood 
pressure otherwise generated by Ang I, notably 
the nonapeptide, teptrotide. Teprotide was 
subsequently widely studied in animals and man. 
Ondetti, Rubin, and Cushman subsequently 
designed a new class of specific ACE inhibitors 
[14]. ACE inhibitors ushered in a new age of 
cardiovascular pharmacotherapy. Another 
plausible target was the Ang II receptor (termed 
AT1 receptor). Pals, Masucci, Sipos, and Denning 
synthesized Sar-Ala-angiotensin, a peptide Ang II 
receptor blocker (ARB) better known as saralasin 
[15]. However, peptide ARBs proved to be not 
practicable. The development of modern ARBs led 
to the identification of Ang II receptor subtypes 
(AT1 and AT2 receptors) [16]. The development of 
2-n-butyl-4-chloro-5-hydroxy-methyl-1-[(2′-(1H-
tetrazol-5-yl)biphe nyl-4-yl) methyl] imidazole 
potassium salt ushered in another era of renin–
angiotensin system inhibition [17]. 
The molecular cloning of a mouse submaxillary 
gland renin cDNA fragment by Pierre Corvol’s 
group ushered in our knowledge of the renin 
gene [18]. That discovery also led to the 
appreciation of the mouse submaxillary renin [19], 
that in turn led to the first utilitarian transgenic 
model of hypertension [20]. The AT1 receptor was 
cloned 1 year later [21]. Thereafter, the progress is 
prodigious. The rest of the story is more or less 
contemporary and will unfold as part of this 
thematic issue of Journal of Molecular Medicine. 
Important parts include the cloning and 
characterization of the (pro)renin receptor, the 
discovery of ACE2, the identification of other 
angiotensins, already a theme in the 1978 
symposium [21], and characterization of the Mas 
receptor. Also a fitting postlude to this 
introductory editorial is the long-awaited 
development of direct renin inhibitors. That 
chapter required the engineering of a novel 
animal model, inconceivable to the participants of 
the 1978 symposium. For me, a notable pleasure 
has been to personally know or have known some 
of the pivotal personalities mentioned here. They 
include Oscar Helmer, Myron Weinberger, George 
Pickering, Merlin Bumpus, Irvine Page, Sérgio 
Ferreira, Marc de Gasparo, Detlev Ganten, John 
Luetscher, John Vane, John Laragh, Jean Sealey, 
Jacques Genest, Tadashi Inagami, Kazuo 
Murakami, David Bohr, Joel Menard, and Pierre 
Corvol. I regret that I could not know Franz Gross 
personally; however, many of the participants of 
this symposium did. Gross would have surely 
livened the sessions! 
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►Fig.1. Franz Gross’ hypothesis from 1958 is shown. I have taken the 
liberty of translating his German into English. With remarkable 
insight, Gross reasoned that the signal between renin and 
aldosterone release (dashed arrow) had to be Ang II. 
 
